HALLE (SAALE) / MUNICH, Germany, 06 January 2021 – in connection with the conversion into an N.V., a public company under the laws of the Netherlands (naamloze […]
HALLE (SAALE) / MUNICH, Germany, 16 December 2020 – as a consequence of the conversion into an N.V., a public company under the laws of the Netherlands […]
HALLE (SAALE) / MUNICH, GERMANY, 14 December 2020 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; ISIN DE0007921835) has been informed by Hauck & Aufhäuser Privatbankiers AG […]
HALLE (SAALE) / MUNICH, Germany, 30 November 2020 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY) announced today that it has completed its conversion into an N.V., a […]
HALLE (SAALE) / MUNICH, Germany, 26 November 2020 – Vivoryon Therapeutics AG (Euronext Amsterdam: VVY; ISIN DE0007921835) announced today its third quarter business update for the period […]
HALLE (SAALE) / MUNICH, Germany, 19 November 2020 – Vivoryon Therapeutics AG (Euronext Amsterdam: VVY, ISIN DE0007921835), a biotechnology company focused on developing first-in-class therapeutics targeting post-translational modifying […]
All proposed resolutions approved with large majority HALLE (SAALE) / MUNICH, Germany, 01 October 2020 – Vivoryon Therapeutics AG (Euronext Amsterdam: VVY, ISIN DE0007921835) announced today […]
HALLE (SAALE) / MUNICH, GERMANY, 3 September 2020 – Vivoryon Therapeutics AG (Euronext Amsterdam: VVY, ISIN DE0007921835) invites all shareholders to Vivoryon Therapeutics´ ordinary general meeting of […]
Vivoryon Therapeutics intends the transfer of the statutory seat to Amsterdam, the Netherlands, leading to a conversion into a public company under the laws of the […]